abstract |
Methods for controlling hypoxia-inducible transcription factor 1-alpha activity (HIF-1a) and related diseases, conditions or syndromes are described, among others, peripheral vascular disease (PVD), coronary artery disease (CAD) , heart failure, ischemia and anemia; In addition, pharmaceutical compositions comprising HIF-prolyl hydroxylase inhibitors useful in the treatment of diseases, conditions and / or syndromes related to the activity of HIF-1a are described. |